Resveratrol is a bioactive plant compound that has drawn scientist and media attention due to its protective effects against a wide variety of illnesses, including cardiovascular diseases and cancer. In the last two decades, a plethora of preclinical studies have shown these beneficial effects, and some of them have been supported by clinical trials.
Introduction
Resveratrol is the parent compound of the stilbene family of molecules, which include glycosides (piceid) and polymers (viniferins), found mainly in grape and grape products, such as red wine, and in very low amounts in peanuts, pistachios, some berries, beer, tomato skin, chocolate and apple. [1] [2] [3] [4] [5] Interest in resveratrol in nutrition and medicine started in 1992 when it was proposed to explain some of the cardiovascular protective effects of red wine in the French Paradox. 6 Since then, the scientific literature on resveratrol has exponentially increased, 7 and thousands of studies, especially in in vitro and in animal models, have investigated its potential activities regarding the prevention or delay of cancer, cardiovascular and neurodegenerative diseases, and aging. Despite the intensive research, few clinical trials on humans have been performed to date. These preclinical and clinical studies have shown that resveratrol exerts several potential beneficial activities such as the improvement of inflammatory and oxidative stress markers, glucose metabolism, and endothelial function, inhibiting platelet aggregation, modulating signaling pathways (e.g., increasing Sirtuin 1 expression), inducing apoptosis and inhibiting angiogenesis, metastasis, and tumor growth. A recent review extensively summarizes the findings from these investigations. 8 Experimental studies mostly use pharmaceutical doses of nutrients/compounds, whereas large epidemiological studies, whether observational or interventional, give insight into the effects of dietary doses. The main limitation of these studies is the inaccuracy in the assessment of nutrient/compound exposure leading to discrepancies in the final findings between studies. The main method to assess dietary exposure is dietary questionnaires and/or biomarkers. 9 The aim of the current article is to review the dietary assessment methodologies for measuring resveratrol exposure and critically evaluate their pros and cons. Furthermore, results of epidemiological studies on resveratrol and health effects obtained by dietary questionnaires or biomarkers are summarized and compared.
Resveratrol and piceid exposure assessment through dietary questionnaires
In nutritional studies, the traditional method to estimate dietary intake of certain nutrient/compound is through dietary questionnaires and a food composition table.
Researchers are usually interested in long term exposure and therefore the surveys most commonly used are single food frequency questionnaires (FFQs), food propensity questionnaires, diet histories, multiple 24-h recalls and 3-or 7-day food records.
The advantages of this approach are the relatively low cost, the ease and simplicity of completing the questionnaires and processing the data, and finally, the large amount of dietary data gathered together, including nutrients, foods and even dietary patterns. The main limitation of the questionnaires is that they are mostly self-reported, so they are based on memory of the subjects and their ability to estimate food portion sizes. 10 However, the use of new technologies is facilitating and improving the accuracy of the subjects" responses, such as "personal digital assistant-", "mobile-phone-", "interactive computer-", "web-", "camera-and tape recorder-", and "scan and sensor-based"
technologies. 11 The second drawback is related to the limited food composition data available and the high variability of composition, particularly for micronutrients and phytochemicals, between similar foods, and even in the same type of food.
Food composition data on resveratrol and piceid
To the best of our knowledge, Phenol-Explorer is the only food composition database containing data on resveratrol and piceid so far. strawberries (14%) and white wine (12%). 18 Our group has also estimated the intake of resveratrol and piceid in the InCHIANTI (Invecchiare in Chianti, Aging in Chianti) study, a cohort of approximately 1,000 men and women, aged ≥ 65 years, and recruited in two small towns in the Tuscany (Italy). 19 Dietary data was collected using a validated food frequency questionnaire every three years starting from 1998-2000. PhenolExplorer was also used to estimate the resveratrol and piceid intake. Mean (SD) intakes of resveratrol and piceid were 0.29 (0.38) and 0.76 (1.05) mg/d respectively (unpublished data). Again, red wine was the main food source, accounting for >90% of total resveratrol and piceid.
To date, epidemiological studies assessing dietary resveratrol and piceid intake have shown similar results in Mediterranean countries since they usually have a high consumption of red wine, such as in France, Spain and Italy. However, in the Polish study, the mean intake was at least 9-fold lower than in Mediterranean. Further descriptive analyses are needed to estimate the intake of resveratrol and piceid in nonMediterranean countries, where greater variability in wine consumption, especially red wine, is found.
Resveratrol and piceid exposure assessment through biomarkers
In modern nutritional epidemiology, there has been intense interest in the discovery, validation and use of nutritional biomarkers. They can be generally defined as a biochemical indicator of recent or long term dietary intake/nutritional status. 20 The main advantage of using nutritional biomarker instead of dietary questionnaires is that they are objective and do not rely on biases or errors of subjects" responses. An "ideal" dietary biomarker would accurately reflect its dietary intake level and it would be specific, sensitive and applicable to many populations. 21 The disadvantages of nutritional biomarkers are the necessity of biological samples, the complexity of the analytical methodology, and mostly, the high cost. 21 Nutritional biomarkers can be classified into several types: recovery (e.g., doubly labeled water, urinary nitrogen and potassium), predictive (e.g., 24 h urinary sucrose and fructose), concentration and replacement biomarkers (e.g., vitamins, individual fatty acids, and phytoestrogens). 22 Despite the advantages of nutritional biomarkers compare to dietary surveys, few nutritional biomarkers have been validated so far. 22 In order to discover a biomarker of dietary resveratrol intake it is essential to have a comprehensive knowledge of resveratrol bioavailability and an analytical technique which allows resveratrol and resveratrol metabolites to be measured at low concentrations in biospecimens.
Bioavailability of resveratrol
Piceid, after hydrolysis of the sugar moiety, and resveratrol are usually absorbed in the small intestine. They are almost totally metabolized in the gut mucosa and the liver and conjugated to glucuronide and sulfate groups. Unabsorbed resveratrol reaches the colon and is converted to dihydroresveratrol by the microbiota. Then, it is absorbed, conjugated and found in the systemic circulation. 23, 24 Finally, around 75% of these metabolites are excreted in urine and feces. 25 Pharmacokinetics studies have shown that the maximum concentrations in urine of resveratrol and piceid metabolites are 30-60 min and 6 h after dietary doses in humans, respectively. 26, 27 Resveratrol and piceid standards are recovered in urine at similar percentages. 28 At nutritional doses (<5mg/day), the absorption of resveratrol is higher than at pharmaceutical doses (from one hundred to thousands mg/day).
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Methodology for assessment resveratrol in biospecimens
A sensitive, precise, selective and robust analytical method is essential to measure resveratrol in biological samples. Instrumentation is usually gas or liquid chromatography coupled to a single or a tandem mass spectrometer. Nowadays, an enzymatic or acidic hydrolysis is no longer performed, since we are interested in identifying and quantifying resveratrol metabolites (glucuronides and sulfates). Our group developed a method of characterizing the complete profile of resveratrol in urine using high performance liquid chromatography coupled to electrospray tandem mass spectrometry (LC-ESI-MS/MS) after a sample clean-up with solid-phase extraction (SPE). 30 It was further improved to identify more resveratrol metabolites in a shorter chromatography run-time and was also adapted to 96-well SPE plates to allow a greater daily throughput. 31 Using this methodology, we are able to identify 21 resveratrol derivatives, including resveratrol, dihydroresveratrol, piceid and their glucuronide-and sulfate-conjugated metabolites (Figure 1 ). 26 Later two microbial metabolites, 3,4'-dihydroxy-trans-stilbene and 3,4'-dihydroxybibenzyl dihydroresveratrol, have been reported using a similar method.
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Most analytical techniques used so far quantified resveratrol in biological samples only after an enzymatic hydrolysis, 33, 34 and could not therefore measure the entire profile of resveratrol metabolites. Subsequent analytical methods were developed to measure the resveratrol metabolite profile in biospecimens, but after the intake of pharmaceutical doses and profiling fewer resveratrol metabolites.
27, 35
Validation studies of resveratrol biomarker
There are several steps for validating a nutritional biomarker. The first one is to get an extensive knowledge of the bioavailability of resveratrol, especially the time-and doseresponse curves, after a single dose. This information is mostly provided by pharmacokinetic studies using resveratrol and resveratrol-rich foods (such as wine and grape juice). These studies have been reviewed previously.
8, 36
The second step is moving from acute to chronic studies. In a double-blind, placebocontrolled study in 40 healthy men and women, after pharmacological doses of resveratrol (six-daily intake of resveratrol capsules [25, 50, 100 or 150 mg] at 4 h intervals) for 13 days, half-lives of plasma resveratrol were 1-3 and 2-5 hours following single-doses and repeated doses, respectively. Maximal plasma concentrations were almost directly proportional to resveratrol intake. High inter-individual variability and circadian variation were also observed. 37 Another study administered capsules containing 0.5, 1, 2.5 or 5 g micronized resveratrol daily for 29 days to healthy men (n=22) and women (n=18) and identified resveratrol-3-O-sulfate, resveratrol-4"-and 3-O-glucuronide as the main plasma metabolites. Moreover, for micronized resveratrol formulation, resveratrol with reduced particle size, maximal plasma levels of resveratrol and derived-metabolites were 3.6x higher than previously published values for standard resveratrol. 38, 39 Our group has also carried out several randomized, crossover trials P=0.005) after consumption of sparkling, white, and red wine, respectively, while the concentration of these metabolites did not vary significantly after the washout and the control periods. 40 The third step is to correlate long-term dietary resveratrol intake using dietary questionnaires and resveratrol concentrations in biological samples in free living populations using large epidemiological studies. To the best of our knowledge, only two observational studies have assessed the usefulness of the resveratrol biomarker so far. In the PREDIMED study, a subsample of 1,000 men and women was evaluated, showing that concentrations of resveratrol metabolites in spot urine were highly correlated with dietary resveratrol intake (r=0.89; P < 0.001). 38 The measurement of urinary resveratrol metabolites could discriminate wine consumers (resveratrol consumers) from non-wine consumers (sporadic or non-resveratrol consumers) with a sensitivity of 93.3% (95% CI, 91.5-94.7%) and a specificity of 92.1% (95% CI, 90.2-93.7%) using a cut-off of 411.4 nmol/g creatinine. 41 In the InCHIANTI study, 783 men and women, aged 65 years and older, were included in the analysis and the correlation coefficient between dietary intake of resveratrol and total resveratrol metabolites in urine 24-h was 0.67 (P < 0.001). 42 Combining all these studies, we can confirm that the sum of all urinary resveratrol metabolites is a valid concentration biomarker of total dietary resveratrol intake.
However, further investigations are needed to assess the potential utility of plasma resveratrol concentrations as a biomarker of resveratrol intake in large observational studies.
Resveratrol and health effects: epidemiological evidence
Although thousands of in vitro and in vivo animal studies 7 and a few dozen intervention trials in humans 8 evaluating the potential mechanisms and molecular targets of resveratrol action, few data come from large epidemiological studies. In this section, we review the available evidence concerning potential protection by resveratrol exposure, which can be estimated using dietary questionnaires and/or nutritional biomarkers, against mortality and chronic disease risk.
Urinary resveratrol metabolite profiles and total dietary resveratrol intake were not associated with overall mortality after 9 years of follow-up in 783 community-dwelling men and women 65 years or older participating in the InCHIANTI study. 42 However, in the PREDIMED study, high total resveratrol intake decreased 50% all-cause mortality in approximately 7,500 men and women at high cardiovascular risk after a mean followup of 4.8 years. 43 In this study, the dose-response effect was borderline significant, but the only significant results were observed with the highest quintile (>5.75mg/day), while in the InChianti study the resveratrol intake was lower and the results were presented in quartiles.
Surprisingly, no association was observed between resveratrol intake and cardiovascular events (nonfatal acute myocardial infarction, nonfatal stroke or death from cardiovascular causes) in the same PREDIMED study. 44 Similar null results were observed in the InCHIANTI study. 42 Indeed in the InCHIANTI study, no association was observed between urinary resveratrol and inflammatory markers (CRP, IL-6, IL-1β, and TNF-α) 42 that are well-known predictors of cardiovascular diseases. 45, 46 Regarding other cardiovascular risk factors, total urinary resveratrol metabolites were inversely associated with glucose and triglyceride levels, and heart rate, but no association was observed with cholesterol levels and blood pressure in a subsample of 1,000 men and women in the PREDIMED study. 47 However, in an Iranian cross-sectional study on 2,618 adult men and women, metabolic syndrome, waist circumference, blood pressure, glucose, triglyceride and HDL levels were not related to dietary resveratrol intake;
hypertension was even positively associated with resveratrol intake. 48 Null results in this study could be due to very low intake of resveratrol (0.002mg/day) in this country.
In China, a cross-sectional study in 1,393 men and women, aged from 35 to 75 years, dietary resveratrol intake from fruits, vegetables and nuts was not associated with cardiovascular factors (such as carotid intima-media thickness, blood pressure, and serum glucose and lipids). 49 The main limitation of this Chinese study is that resveratrol from wine and grape juice was not considered, which are by far the major food sources in wine consumer countries. 1 Few studies have looked for associations between resveratrol exposure and cancer risk
In the InCHIANTI study, no association was observed between both urinary and dietary resveratrol and prevalent or incident overall cancer risk after 9 years of follow-up. 42 In the SU.VI.MAX cohort, dietary resveratrol was not related to breast cancer risk in nearly 4,150 women with a median follow-up of 12.6 years. 50 However, in the Swiss
Canton of Vaud case control study, including 369 cases and 602 controls, breast cancer risk was inversely associated with dietary resveratrol from grapes but not from wine. 51 This could be explained because alcohol is a well-known risk factor for breast cancer, 52 and it may mask the effects of resveratrol. Furthermore, a study has evaluated the relationship between resveratrol intake and lung function in two large Dutch cohorts. 53 The Doetinchem (n=1,152) and Vlagtwedde-Vlaardingen (n=1,390) studies suggest an inverse association between dietary resveratrol and force vital capacity (FVC), but not with forced expiratory volume in 1 second (FEV1). Similarly, no significant association of resveratrol intake with the presence of airway obstruction, as present in chronic obstructive pulmonary disease, was found.
In general, no associations were observed in most of the epidemiological studies so far, and it is possible that nutritional doses of resveratrol are too low to have the protective effects found at pharmacological doses (hundred milligrams to grams) in preclinical and clinical trials. Measurement error in the assessment of resveratrol exposure may also attenuate the results towards the null results. Furthermore, other compounds more abundant or with stronger effect may mask the effect of resveratrol, such alcohol, and other polyphenols. However, some protective effects against cardiovascular risk factors were suggested, such as the improvement of glucose and triglyceride levels and heart rate, although the evidence is still scarce.
Conclusions
Resveratrol is a fashionable bioactive compound that has been reported to exert a myriad of health benefits through many different mechanisms of action and molecular targets, mostly reported in vitro and in animal (preclinical) studies. In clinical trials, there is growing evidence that resveratrol could exert cardioprotective effects particularly through the improvement of inflammatory markers, atherogenic profile, glucose metabolism and endothelial function. However, a few epidemiological studies have assessed the potential relationships between dietary resveratrol and the risk of cardiovascular and other chronic diseases. It is mainly due to the limitations for assessing properly dietary exposure of resveratrol. Phenol-Explorer is the first database containing food composition data on resveratrol and its derivatives. It will facilitate the estimation of resveratrol intake in large epidemiological settings. Moreover, the discovery and validation of a nutritional biomarker, urinary resveratrol, will allow resveratrol exposure to be objectively measured. The combination of dietary and urinary data on resveratrol will also improve the exposure estimations and, consequently, increase the strength of the findings. 54 Results from epidemiological studies are limited and still inconclusive, although some protective effects against cardiovascular diseases were suggested. Further studies are warranted to evaluate the associations with chronic diseases, taking into account current advances in the estimation of dietary resveratrol exposure. 
